Otsuka Holdings Co., Ltd. (OTSKY) ( (OTSKY) ) has released its Q4 earnings. Here is a breakdown of the information Otsuka Holdings Co., Ltd. (OTSKY) presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Otsuka Holdings Co., Ltd. is a global healthcare company based in Japan, operating in the pharmaceutical and nutraceutical sectors, known for its innovative approach in combining nutrition with pharmaceuticals. In its fiscal year 2024 earnings report, Otsuka Holdings has shown substantial financial growth, highlighted by a 15.4% increase in revenue year-over-year, reaching ¥2,329.9 billion. This growth was driven by strong performances in both its pharmaceutical and nutraceutical businesses. Key financial metrics include a significant rise in business profit by 37.7% to ¥430.5 billion and a net profit increase of 182.1% to ¥343.1 billion, partly due to one-time tax adjustments in the U.S. Notably, the pharmaceutical segment saw a 17.1% revenue increase, with notable gains in products such as ABILIFY MAINTENA, REXULTI, and JYNARQUE. The nutraceutical business also grew by 15.2%, with a strong focus on women’s health products. Looking ahead, Otsuka Holdings aims to continue its growth trajectory, with plans to exceed FY2024’s revenue, driven by sustained growth in its core pharmaceutical and nutraceutical operations.
